<DOC>
	<DOCNO>NCT01135498</DOCNO>
	<brief_summary>This study evaluate efficacy safety first-line regimen Avastin Xelox ( Xeloda + Eloxatin ) follow Avastin Tarceva , patient metastatic colorectal cancer . Patients receive 6 x 21 day cycle treatment Avastin ( 7.5mg/kg iv day 1 ) , Xeloda ( 1000mg/m2 po twice daily day 1 14 ) Eloxatin ( 130mg/m2 iv day 1 ) . Patients free disease progression continue Avastin ( 7.5mg/kg iv every 3 week ) Tarceva ( 150mg po daily ) . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Xelox Tarceva Patients With Metastatic Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; adenocarcinoma colon rectum , metastatic disease ; &gt; =1 measurable lesion . previous treatment Avastin Tarceva ; previous systemic treatment advance metastatic disease ; adjuvant treatment nonmetastatic disease past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>